Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma by Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Usmani, Mei Dong, Lin Gu, Carmen Leung, Parul Doshi, Christine Chen, Ludek Pour

Get full text

Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup by Chandramouli Nagarajan, Natasha Fay Anthony, Jens Hillengass, Seok Jin Kim, Chutima Kunacheewa, Jay T. Datukan, Gin Gin Gan, Vo Thi Thanh Binh, James Chim, Jeffery S.Y. Huang, Wenming Chen, Kihyun Kim, S. Vincent Rajkumar, Brian G.M. Durie, Wee Joo Chng, Masahiro Abe

Get full text

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐u... by Elias K. Mai, Axel Nogai, Henk M. Lokhorst, Bronno van derHolt, Sonja Zweegman, Katja C. Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens‐Kroef, Marc S. Raab, Annemiek Broijl, Gerard M. J. Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J. Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld

Get full text